Paracoccidioidomycosis

Summary

Paracoccidioidomycosis (MONDO:0005894) is a disease and 1 clinical trial. A subtype of primary systemic mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paracoccidioidomycosis
Mondo ID	MONDO:0005894
EFO	EFO:0007417
MeSH	D010229
Orphanet	73260
DOID	DOID:12662
ICD-10-CM	B41
ICD-11	268777657
NCIT	C34891
SNOMED CT	36866003
UMLS	C0030409
MedGen	14601
GARD	0007323
MedDRA	10061906
NORD	1553
Is cancer (heuristic)	no

Also known as: lobo disease · Lutz-Splendore-Almeida disease · Paracoccidioidal granuloma · PCM · South American blastomycosis

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › systemic mycosis › primary systemic mycosis › paracoccidioidomycosis

Related subtypes (5): adiaspiromycosis, allescheriosis, blastomycosis, coccidioidomycosis, histoplasmosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06523998	Not specified	COMPLETED	A Study on Rare Dermatological Infections Conducted at Three Major Reference Hospitals in Costa Rica.